JUN 20, 2018 1:30 PM PDT

Regulation of Precision Medicine

Speaker
  • Counsel, Potomac Law Group
    Biography
      Neil A. Belson is Of Counsel at Potomac Law Group, in Washington, D.C., where he handles transactional and regulatory compliance matters. He focuses on Precision Medicine, Life Sciences and Information Technology. Mr. Belson has also been an entrepreneur, and has founded, run and sold an industrial biotechnology business.
      Mr. Belson received his J.D. cum laude from Harvard Law School, and received B.S. and M.S. degrees from the University of Maryland. Mr. Belson also served as a Peace Corps Volunteer in the Dominican Republic.

    Abstract

    Regulation of precision medicine is rapidly evolving.  The pre-existing regulatory framework did not contemplate many of the products and technologies which are becoming available with precision medicine.   FDA and other federal agencies have responded by attempting to develop a “flexible and adaptive” approach to regulation which simultaneously encourages innovation while still assuring that new precision medicine drugs and medical devices are safe and effective.
     
    FDA has issued a series of non-binding “Guidance Documents” addressing different topics in precision medicine.   While non-binding, these guidance documents explain the Agency’s current thinking on specific issues and should be viewed as recommendations.

    FDA in 2017 issued a Guidance Document relating to the use of “Real World Evidence” (RWE) to support regulatory decisions involving medical devices.   RWE represents a potentially faster, less expensive and more useful alternative to traditional randomized clinical trials (RCT’s) for generating data to support regulatory approvals of drugs and devices.  RWE consists of clinical evidence of a product's usage, benefits and risks obtained from an analysis of real-world data sources, such as patient EHR’s, insurance claims data and disease or device registries.  In 2017, FDA approved a new indication for a medical device based entirely on RWE.   

    FDA has recently issued Guidance Documents and draft guidances covering many other aspects of precision medicine, including NGS–based tests, genetics variant databases and companion diagnostics.  Additionally, FDA and CMS have developed a parallel review process for devices aimed at allowing developers to concurrently obtain both marketing approval and eligibility for Medicare coverage. 

    Many of FDA regulatory guidances have issued within the last 12 months.  It is likely that regulation of precision medicine will continue its evolution for the foreseeable future.


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    JUN 20, 2018 1:30 PM PDT

    Regulation of Precision Medicine


    Specialty

    Cancer Research

    Gene Expression

    Mass Cytometry

    Anatomy

    Dna

    T-Cells

    Cancer Diagnostics

    Immunotherapeutics

    Bioinformatics

    Virology

    Clinical Lab

    Laboratory Testing

    Immunology

    Personalized Medicine

    Drug Discovery

    Geography

    Europe50%

    South America50%

    Registration Source

    Website Visitors100%

    Job Title

    Student50%

    QC/QA50%

    Organization

    Independent Laboratories50%

    Academic Institution50%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more